This activity was originally presented at the 2024 HOPA Annual Conference in Tampa, Florida.
Program Description
Cytogenetic risk classification based on routine blood tests forms the basis of the standard treatment paradigm in lower-risk MDS (LR-MDS) and requires the involvement of oncology pharmacists to individualize treatment management. Treatment goals center on symptom improvement and achieving transfusion independence, yet patients with MDS frequently experience complications, including anemia with transfusion dependence, transfusional iron overload requiring iron chelation therapy, and disease progression/leukemic transformation, among others. Several recently approved and emerging agents could overcome and mitigate these challenges as alternatives to erythropoiesis-stimulating agents and red blood cell transfusions. Clinical pharmacists within oncology practice settings play key roles in implementing novel therapies into treatment paradigms as they contribute to updates of treatment and education protocols, provide patient counseling, and assist with supportive care for newly approved therapies. This educational activity will center around recent and relevant data to provide oncology pharmacists with up-to-date information and insights into newly emerging therapies and treatment protocols in LR-MDS. Included patient case discussions will establish the role of oncology pharmacists in symptom improvement, enhancing quality of life, and prolonging survival for patients with LR-MDS.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 12, 2024
Expiration date: April 12, 2025
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the efficacy and clinical utility of emerging treatment strategies for lower-risk myelodysplastic syndromes (LR-MDS) through the interpretation of recent and emerging clinical evidence
- Construct personalized treatment plans for patients with LR-MDS considering patient preference and disease-related complications
- Optimize systemic therapy for patients with LR-MDS through appropriate dosing and therapeutic adjustments relative to treatment response and tolerability
- Practice with interdisciplinary health care teams to ensure the seamless integration of supportive care interventions into the overall LR-MDS patient care plan
Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan
Rachel Feaster, PharmD, BCOP, BCPS
Clinical Oncology Pharmacist
Fred Hutchinson Cancer Center
Seattle, Washington
Firas El Chaer, MD
Assistant Professor of Medicine
Medical Director of Chronic & Acute Leukemia, MDS & MPN Clinical Research Team
Infusion Center Medical Director
Division of Hematology & Oncology
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-097-H01-P. The activity is available for CE credit through April 12, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Firas El Chaer, MD, has the following relevant financial relationships with commercial interests to disclose:
Consultant: AbbVie, Amgen, Bristol Myers Squibb, CTI Biopharma, MorphoSys, PharmaEssentia, SPD Oncology
Other support: Arog Pharmaceuticals, BioSight, Celgene, FibroGen, MEI Pharma, Novartis, Sanofi
Anthony J. Perissinotti, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: AbbVie, Amgen, Servier
Rachel Feaster, PharmD, BCOP, BCPS, has the following relevant financial relationship with a commercial interest to disclose:
Medical writing: GoodRx
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no financial relationships with commercial interests to disclose.
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here